Lucid Diagnostics (LUCD) said Monday it now has until June 16, 2025, to regain compliance with Nasdaq's minimum bid price requirement for continued listing requirements following a 180-day extension.
To regain compliance, Lucid Diagnostics must maintain a closing bid price of at least $1 per share for at least 10 consecutive business days.
The PAVmed (PAVM) subsidiary said it plans to "take all appropriate actions" to regain compliance with Nasdaq's listing rules within the extension period and that its shares will continue trading on the bourse under the "LUCD" ticker.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments